Corcept Therapeutics Incorporated Stock Performance
| CORT Stock | USD 51.66 0.80 1.57% |
On a scale of 0 to 100, Corcept Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 1.17, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Corcept Therapeutics will likely underperform. Please check Corcept Therapeutics' value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Corcept Therapeutics' price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Corcept Therapeutics Incorporated are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Corcept Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.58 | Five Day Return 2.05 | Year To Date Return 3.38 | Ten Year Return 1.7 K | All Time Return 322.4 |
1 | Recent Price Trend in Corcept is Your Friend, Heres Why | 11/04/2024 |
2 | Disposition of 30000 shares by Guyer William of Corcept Therapeutics at 19.26 subject to Rule 16b-3 | 11/13/2024 |
3 | Acquisition by Gary Robb of 1818 shares of Corcept Therapeutics subject to Rule 16b-3 | 11/22/2024 |
4 | Disposition of 182 shares by Atabak Mokari of Corcept Therapeutics at 57.68 subject to Rule 16b-3 | 12/02/2024 |
5 | Disposition of 2200 shares by Swisher Daniel N Jr of Corcept Therapeutics at 59.46 subject to Rule 16b-3 | 12/10/2024 |
6 | Corcept Phase 2 study of ALS drug fails to meet primary endpoint | 12/11/2024 |
7 | Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism and Difficult-to-Control Diabetes | 12/12/2024 |
8 | Corcept Therapeutics FDA-Approved Korlym Hits Main Goal In Cushings Syndrome Patients With Difficult-To-Control Diabetes | 12/13/2024 |
9 | CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period DelveInsight | 12/16/2024 |
10 | Geode Capital Management LLC Purchases 99,470 Shares of Corcept Therapeutics Incorporated | 12/19/2024 |
11 | Disposition of 7800 shares by Wilson James N of Corcept Therapeutics subject to Rule 16b-3 | 12/27/2024 |
12 | Corcept Submits Application for Another Cushings Syndrome Drug | 12/31/2024 |
| Begin Period Cash Flow | 66.3 M | |
| Free Cash Flow | 126.9 M |
Corcept |
Corcept Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,578 in Corcept Therapeutics Incorporated on October 8, 2024 and sell it today you would earn a total of 508.00 from holding Corcept Therapeutics Incorporated or generate 11.1% return on investment over 90 days. Corcept Therapeutics Incorporated is currently generating 0.2078% in daily expected returns and assumes 2.7912% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Corcept, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Corcept Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Corcept Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Corcept Therapeutics Incorporated, and traders can use it to determine the average amount a Corcept Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0744
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CORT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.79 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Corcept Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Corcept Therapeutics by adding it to a well-diversified portfolio.
Corcept Therapeutics Fundamentals Growth
Corcept Stock prices reflect investors' perceptions of the future prospects and financial health of Corcept Therapeutics, and Corcept Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Corcept Stock performance.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 4.95 B | ||||
| Shares Outstanding | 104.78 M | ||||
| Price To Earning | 30.07 X | ||||
| Price To Book | 8.34 X | ||||
| Price To Sales | 8.48 X | ||||
| Revenue | 482.38 M | ||||
| Gross Profit | 396.47 M | ||||
| EBITDA | 108.32 M | ||||
| Net Income | 106.14 M | ||||
| Cash And Equivalents | 370.09 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 151 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.54 X | ||||
| Book Value Per Share | 6.10 X | ||||
| Cash Flow From Operations | 127.04 M | ||||
| Earnings Per Share | 1.26 X | ||||
| Market Capitalization | 5.33 B | ||||
| Total Asset | 621.52 M | ||||
| Retained Earnings | 402.53 M | ||||
| Working Capital | 354.13 M | ||||
| Current Asset | 48.98 M | ||||
| Current Liabilities | 20.88 M | ||||
About Corcept Therapeutics Performance
Assessing Corcept Therapeutics' fundamental ratios provides investors with valuable insights into Corcept Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Corcept Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 500.64 | 475.61 | |
| Return On Tangible Assets | 0.15 | 0.16 | |
| Return On Capital Employed | 0.19 | 0.20 | |
| Return On Assets | 0.15 | 0.16 | |
| Return On Equity | 0.19 | 0.20 |
Things to note about Corcept Therapeutics performance evaluation
Checking the ongoing alerts about Corcept Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Corcept Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Corcept Submits Application for Another Cushings Syndrome Drug |
- Analyzing Corcept Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Corcept Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Corcept Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Corcept Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Corcept Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Corcept Therapeutics' stock. These opinions can provide insight into Corcept Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.